Want to see VCYT full AI Analyst Report?
VCYT Stock Chart & Stats
$33.80
$0.68(1.60%)
At close: 4:00 PM EST
$33.80
$0.68(1.60%)
Day’s Range― - ―
52-Week Range$22.92 - $60.91
Previous CloseN/A
Volume253.49K
Average Volume (3M)1.31M
Market Cap
$4.75B
Enterprise Value$2.22K
Total Cash (Recent Filing)$439.06M
Total Debt (Recent Filing)$39.33M
Price to Earnings (P/E)52.5
Beta1.18
Next Earnings
Jul 30, 2026EPS Estimate
0.43Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.11
Shares Outstanding79,792,650
10 Day Avg. Volume1,114,929
30 Day Avg. Volume1,314,285
Financial Highlights & Ratios
PEG Ratio0.31
Price to Book (P/B)2.53
Price to Sales (P/S)6.40
P/FCF Ratio26.13
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda<0.01
Forecast
1Y Price Target
$59.00Price Target Upside74.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering10
EPS Forecast (FY)1.81
Revenue Forecast (FY)$586.37M
Bulls Say, Bears Say
Bulls Say
Conservative Balance SheetA very low debt burden and a large equity base give Veracyte durable financial flexibility. Improved ROE from negative to positive indicates the company can deploy capital more effectively, funding launches or absorbing reimbursement delays without urgent external financing.
Strong Cash Generation & LiquidityConsistent positive operating cash flow and a sizable cash reserve provide a sustainable runway for commercialization and R&D. This liquidity supports product launches, marketing investments, and shields the business from short-term PPC or seasonality shocks without diluting shareholders.
Decipher Clinical & Commercial MomentumStrong, sustained volume growth for Decipher and a deep clinical evidence base create a durable competitive advantage. High-risk category traction and growing GRID/digital assets support physician adoption, pricing power, and future product extensions across oncology diagnostics.
Bears Say
Binary Clinical Trial RiskKey product rollouts and label enhancements hinge on binary Phase 3 outcomes. An unfavorable or delayed readout would materially impair Prosigna LDT and guideline positioning, slowing adoption, limiting reimbursement, and undermining the launch-driven revenue assumptions over the medium term.
Guideline & Reimbursement Timing UncertaintyEven positive clinical data may not yield prompt guideline updates or payer coverage. Slow reimbursement decisions can delay real-world uptake of new assays, stretching commercialization costs and reducing near-term returns on R&D and sales investments for several quarters.
Decelerating Revenue Growth MomentumRevenue growth has slowed from earlier multi-year gains to mid-single-digit TTM growth. Slower top-line expansion constrains operating leverage upside and raises dependence on upcoming product launches and margin gains to sustain profitability improvements.
Veracyte News
VCYT FAQ
What was Veracyte Inc’s price range in the past 12 months?
Veracyte Inc lowest stock price was $22.92 and its highest was $60.91 in the past 12 months.
What is Veracyte Inc’s market cap?
Veracyte Inc’s market cap is $4.75B.
When is Veracyte Inc’s upcoming earnings report date?
Veracyte Inc’s upcoming earnings report date is Jul 30, 2026 which is in 7 days.
How were Veracyte Inc’s earnings last quarter?
Veracyte Inc released its earnings results on May 05, 2026. The company reported $0.52 earnings per share for the quarter, beating the consensus estimate of $0.334 by $0.186.
Is Veracyte Inc overvalued?
According to Wall Street analysts Veracyte Inc’s price is currently Undervalued.
Does Veracyte Inc pay dividends?
Veracyte Inc does not currently pay dividends.
What is Veracyte Inc’s EPS estimate?
Veracyte Inc’s EPS estimate is 0.43.
How many shares outstanding does Veracyte Inc have?
Veracyte Inc has 79,792,650 shares outstanding.
What happened to Veracyte Inc’s price movement after its last earnings report?
Veracyte Inc reported an EPS of $0.52 in its last earnings report, beating expectations of $0.334. Following the earnings report the stock price went up 24.932%.
Which hedge fund is a major shareholder of Veracyte Inc?
Currently, no hedge funds are holding shares in VCYT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Veracyte Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$59.00 (74.56% Upside)
$59.00 (74.56% Upside)
Blogger Sentiment
Neutral
VCYT Sentiment 50%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 1.4M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $1.1M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▼ 3.1%
Last 30 Days ▲ 4.1%
Last 30 Days ▲ 4.1%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
146.74%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
9.20%
Trailing 12-Months
Company Description
Veracyte Inc
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
VCYT Stock 12 Month Forecast
Average Price Target
$59.00
▲(74.56% Upside)
Technical Analysis
Travere Therapeutics
―
Celcuity
―
Immunovant
―
Arcutis Biotherapeutics
―
Disc Medicine
―
Ownership Overview
1.79% Insiders
34.34% Mutual Funds
0.28% Other Institutional Investors
27.90% Public Companies and
Individual Investors